Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study.
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
Female
Humans
Induction Chemotherapy
Lymphoma, Follicular
/ diagnostic imaging
Male
Middle Aged
Positron-Emission Tomography
Retrospective Studies
Rituximab
/ therapeutic use
Tumor Burden
/ drug effects
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
09 04 2020
09 04 2020
Historique:
received:
11
04
2019
accepted:
07
01
2020
pubmed:
22
1
2020
medline:
3
11
2020
entrez:
22
1
2020
Statut:
ppublish
Résumé
A minority of patients with follicular lymphoma (FL) undergo histological transformation (HT). This retrospective analysis of 549 patients from the phase 3 GALLIUM study (NCT01332968) assessed the relationship between maximum standardized uptake value (SUVmax) at baseline on positron emission tomography (PET) and HT risk. Previously untreated patients with high tumor burden grade 1-3a FL received obinutuzumab- or rituximab-based chemotherapy induction. The relationship between baseline SUVmax (bSUVmax) and HT risk was assessed using cutoff values for SUVmax >10 and >20. Overall, 15 of 549 (2.7%) patients with baseline PET scans experienced biopsy-confirmed HT (median follow-up, 59 months). More than 65% of patients had bSUVmax > 10, with 3.3% of these experiencing HT. Only 1 of 74 (1.4%) patients with bSUVmax > 20 underwent HT. Median bSUVmax in patients with HT vs without HT was 12.4 (range, 8.1-28.0) vs 11.8 (range, 3.1-64.4), respectively; median bSUVrange (the difference between bSUVmax of the most and least 18F-fluorodeoxyglucose-avid lymphoma sites) was 8.0 (range, 1.1-23.9) vs 7.1 (range, 0.0-59.8), respectively. There was no temporal relationship between bSUVmax and HT. Neither bSUVmax nor bSUVrange predicted HT in GALLIUM, suggesting that there may be little benefit in rebiopsy of lesions to exclude HT based on SUVmax alone before initiating therapy in patients with high tumor burden FL.
Identifiants
pubmed: 31961926
pii: S0006-4971(20)62114-0
doi: 10.1182/blood.2019001091
pmc: PMC7146018
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Rituximab
4F4X42SYQ6
obinutuzumab
O43472U9X8
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1214-1218Subventions
Organisme : Department of Health
ID : RP-2016-07-001
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 by The American Society of Hematology.
Références
Nucl Med Commun. 2011 Mar;32(3):177-85
pubmed: 21169873
Ann Oncol. 2009 Mar;20(3):508-12
pubmed: 19139176
Blood. 1997 Jun 1;89(11):3909-18
pubmed: 9166827
Lancet Haematol. 2018 Aug;5(8):e359-e367
pubmed: 30078408
N Engl J Med. 2017 Oct 5;377(14):1331-1344
pubmed: 28976863
J Nucl Med. 2015 Feb;56(2):216-21
pubmed: 25593118
Hematol Oncol Clin North Am. 2007 Oct;21(5):841-54
pubmed: 17908623
Haematologica. 2008 Mar;93(3):471-2
pubmed: 18310543
Ann Oncol. 2009 Sep;20(9):1543-7
pubmed: 19474116
Medicine (Baltimore). 2017 Nov;96(47):e8705
pubmed: 29381956
J Clin Oncol. 2005 Jul 20;23(21):4643-51
pubmed: 15837966
J Clin Oncol. 2016 Aug 1;34(22):2575-82
pubmed: 27298402